Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

5/28/25 7:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $AKRO alert in real time by email

SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 8:45 a.m. P.T.

A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.

About Akero Therapeutics

Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Akero's lead product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies: SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, and SYNCHRONY Real-World in patients with MASH or MASLD (metabolic dysfunction-associated steatotic liver disease). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and X for more information.

Investor Contact:

Christina Tartaglia

Precision AQ

332.322.7430

[email protected]

Media Contact:

Peg Rusconi

617.910.6217

[email protected]

Get the next $AKRO alert in real time by email

Date	Price Target	Rating	Analyst
1/30/2025	$35.00 → $63.00	Neutral → Buy	BofA Securities
1/27/2025	$50.00 → $72.00	Buy	H.C. Wainwright
11/18/2024	$65.00	Buy	Citigroup
4/22/2024	$30.00	Neutral	BofA Securities
9/19/2023	$69.00	Overweight	Cantor Fitzgerald
8/28/2023	$83.00	Buy	UBS
1/27/2023	$40.00 → $65.00	Equal-Weight → Overweight	Morgan Stanley
9/14/2022	$10.00 → $50.00	In-line → Outperform	Evercore ISI

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

Chat with this insight

Recent Analyst Ratings for
$AKRO

$AKRO
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Graham G. Walmsley bought $8,787,921 worth of shares (200,000 units at $43.94) (SEC Form 4)

Director Graham G. Walmsley bought $9,600,000 worth of shares (200,000 units at $48.00) (SEC Form 4)

Graham G. Walmsley bought $1,982,940 worth of shares (100,000 units at $19.83) (SEC Form 4)

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

Chat with this insight

Recent Analyst Ratings for $AKRO

$AKRO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Graham G. Walmsley bought $8,787,921 worth of shares (200,000 units at $43.94) (SEC Form 4)

Director Graham G. Walmsley bought $9,600,000 worth of shares (200,000 units at $48.00) (SEC Form 4)

Graham G. Walmsley bought $1,982,940 worth of shares (100,000 units at $19.83) (SEC Form 4)

Recent Analyst Ratings for
$AKRO

$AKRO
Insider Purchases